Clinical trial
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung…
NCT00374140 · Ahmad Tarhini, Other · Completed
Key facts
| NCT number | NCT00374140 |
|---|---|
| Title | Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer |
| Official title | Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer |
| Lead sponsor | Ahmad Tarhini, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | RAD001 (everolimus) |
| Enrollment | 40 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jun 1, 2012 |
| First posted | Sep 8, 2006 |
| Last update posted | Oct 19, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: